📉 Live Chart
Interactive · powered by TradingView
📊 marketbrief Score For reference
Our own score derived from public financial data, ranked against sector peers. Updated daily.
3.0
/ 5.0
Hold
Grade B-, ranked against 60 peers in the Healthcare sector.
Valuation가치
D
Growth성장
B+
Profitability수익성
C+
Momentum모멘텀
B+
※ This score is informational only and not investment advice. See the methodology page for the formula. Methodology →
✍️ marketbrief View
Gilead Sciences is a leader in HIV and hepatitis treatments, with a solid B+ growth grade, though its P/E shows as effectively meaningless due to earnings-related one-off factors. A 2.17% dividend yield is notably stable for a biotech name.
Its D valuation grade sits near the bottom, likely reflecting both the durability of HIV drug revenue and strong expectations for its oncology pipeline. Tracking patent expiration timelines alongside pipeline progress is important here.
Key Stats
As of last close
Market Cap
$187.1B
PER
—
Dividend Yield
2.19%
52-Week High
$157.29
52-Week Low
$108.46
1-Year Return
+34.6%